GBT Announces Participation at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
Rhea-AI Summary
Global Blood Therapeutics, Inc. (GBT) will present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020, at 3:50 p.m. ET. The presentation will be available via webcast on GBT's official website. GBT, focused on sickle cell disease treatments, has introduced Oxbryta (voxelotor), the first FDA-approved therapy targeting sickle hemoglobin polymerization. The company is also developing inclacumab, aimed at alleviating pain crises associated with SCD. Archived webcasts will be accessible for a month post-event.
Positive
- Introduction of Oxbryta, the first FDA-approved treatment for sickle cell disease.
- Advancing pipeline program with inclacumab to address pain crises related to SCD.
Negative
- None.
News Market Reaction – GBT
In the trading session that priced this news, GBT gained 0.20%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast on Tuesday, June 9, 2020, at 3:50 p.m. Eastern Time.
The presentation will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, an underlying cause of SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com
Stephanie Yao (investors)
650-741-7730
syao@gbt.com